Linked Life Data

8991116

Source:http://linkedlifedata.com/resource/pubmed/id/8991116

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
1997-1-30
pubmed:abstractText
Many Burkitt's-type non-Hodgkin lymphomas (NHL) in patients without HIV infection are curable with current brief high-dose combination chemotherapy regimens. Burkitt's-type lymphomas (BL) comprise 30-40% of HIV-associated NHL. Their morphologic, clinical, cytogenetic and molecular genetic characteristics are similar to those of sporadic BL unassociated with HIV infection. They often occur in less immunosuppressed HIV-infected individuals than the other types of NHL. Most patients with HIV-associated NHL benefit as much from low-dose as from standard or high-dose chemotherapy with less toxicity. However, there may be a subpopulation of HIV-infected patients with Burkitt's-type NHL and well preserved immune status who may benefit from high-dose chemotherapy programs that are effective for BL patients without HIV infection.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:issn
0753-3322
pubmed:author
pubmed:issnType
Print
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
447-50
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Treatment of Burkitt's lymphoma in HIV-positive patients.
pubmed:affiliation
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
pubmed:publicationType
Journal Article, Review